A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Abstract Background Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Satoshi Kobayashi, Taito Fukushima, Makoto Ueno, Satoshi Moriya, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Michihiro Suzuki, Haruki Uojima, Hisashi Hidaka, Chika Kusano, Motoko Suzuki, Manabu Morimoto
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2022-05-01
Saila:BMC Cancer
Gaiak:
Hepatocellular carcinoma
Intermediate stage
Substage
Lenvatinib
TACE
Sarrera elektronikoa:https://doi.org/10.1186/s12885-022-09625-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak